Home » Stocks » LIXT

Lixte Biotechnology Holdings, Inc. (LIXT)

Stock Price: $1.16 USD 0.00 (0.00%)
Updated Oct 23, 2020 9:30 AM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 12.96M
Revenue (ttm) n/a
Net Income (ttm) -2.16M
Shares Out 11.17M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $1.16
Previous Close $1.16
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.16
Day's Range 1.16 - 1.16
Day's Volume 0
52-Week Range 0.6 - 1.2

More Stats

Market Cap 12.96M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 11.17M
Float 3.12M
EPS (basic) n/a
EPS (diluted) -0.03
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta -0.80
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 322.42
Revenue n/a
Operating Income n/a
Net Income -2.16M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -49.54%
ROE -85.04%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Lixte Biotechnology Holdings, Inc.
Country United States
Employees 1
CEO John S. Kovach

Stock Information

Ticker Symbol LIXT
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: LIXT


Lixte Biotechnology Holdings operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primary focuses on developing various treatments for human cancers and other non-malignant diseases, including vascular diseases, such as heart attacks and strokes, and diabetes, as well as genetic diseases comprising Gaucher's disease; and depression and post-traumatic stress syndrome. It develops protein phosphatase inhibitors that include LB-100 series of compounds; and histone deacetylase inhibitors, which comprises LB-200 series of compounds for the treatment of cancer, as well as in the prevention and treatment of neurodegenerative diseases, which are under various stages of pre-clinical and clinical developments. The company has a collaboration agreement with the Foundation for Angelman Syndrome Therapeutics to support the preclinical study of LB-100, a protein phosphatase 2A inhibitor for the treatment of angelman syndrome. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in East Setauket, New York.